Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Wednesday, December 31, 2025.
Limited history available
BLSM Return on Equity (ROE) has fewer than three reported periods, so a trend chart would be misleading.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
44.05%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
BlossomHill Therapeutics, Inc.
Market Cap
$530.63M
Return on Equity (ROE)
N/A
TTM Avg
44.05%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$532.59M
Return on Equity (ROE)
-306.61%
TTM Avg
-169.61%
3Y Avg
-163.97%
5Y Avg
-73.13%
Market Cap
$533.14M
Return on Equity (ROE)
N/A
TTM Avg
91.17%
3Y Avg
180.92%
5Y Avg
76.31%
Market Cap
$527.40M
Return on Equity (ROE)
-60.79%
TTM Avg
-73.94%
3Y Avg
-62.04%
5Y Avg
-71.62%
Market Cap
$525.52M
Return on Equity (ROE)
-17.44%
TTM Avg
-97.25%
3Y Avg
-87.77%
5Y Avg
-77.06%
Market Cap
$536.12M
Return on Equity (ROE)
0.44%
TTM Avg
-17.98%
3Y Avg
71.24%
5Y Avg
-6.51%
Market Cap
$536.32M
Return on Equity (ROE)
N/A
TTM Avg
6.49%
3Y Avg
6.51%
5Y Avg
-75.00%
Market Cap
$520.12M
Return on Equity (ROE)
-19.35%
TTM Avg
-58.07%
3Y Avg
-51.86%
5Y Avg
-46.32%
Market Cap
$543.14M
Return on Equity (ROE)
-24.90%
TTM Avg
-76.97%
3Y Avg
-68.04%
5Y Avg
-50.09%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BlossomHill Therapeutics, Inc. (BLSM) | $530.63M | N/A | 44.05% | N/A | N/A |
| Nuvectis Pharma, Inc. (NVCT)vs › | $532.59M | -306.61% | -169.61% | -163.97% | -73.13% |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $533.14M | N/A | 91.17% | 180.92% | 76.31% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $527.40M | -60.79% | -73.94% | -62.04% | -71.62% |
| Immix Biopharma, Inc. (IMMX)vs › | $525.52M | -17.44% | -97.25% | -87.77% | -77.06% |
| Delcath Systems, Inc. (DCTH)vs › | $536.12M | 0.44% | -17.98% | 71.24% | -6.51% |
| ProKidney Corp. (PROK)vs › | $536.32M | N/A | 6.49% | 6.51% | -75.00% |
| Altimmune, Inc. (ALT)vs › | $520.12M | -19.35% | -58.07% | -51.86% | -46.32% |
| Shattuck Labs, Inc. (STTK)vs › | $543.14M | -24.90% | -76.97% | -68.04% | -50.09% |
| Monopar Therapeutics Inc. (MNPR)vs › | $548.39M | -13.64% | -19.13% | -73.22% | -63.52% |
ROE
N/A
ROA
-37.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 45.97% |
| 2024-12-31 | 42.12% |
